In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria
In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria
复制标题
DOI：
10.1128/aac.47.6.1968-1971.2003
复制
发表时间：
2003-06-01
影响因子：
4.9
通讯作者：
Fernandez, HT
中科院分区：
文献类型：
--
作者：
Goldstein, EJC;Citron, DM;Fernandez, HT
达巴万星是一种新型半合成糖肽，具有增强的抗革兰氏阳性菌活性。它的体外活性比较和9个比较剂，包括达托霉素，万古霉素，利奈唑胺，和奎奴普汀-达福普汀，对290个最近的革兰氏阳性临床分离株，NCCLS琼脂稀释法测定，进行了研究。达巴霉素抑制90%测试的各种分离株的MIC如下：放线菌属，0.5梭状芽胞杆菌8 μ g/ml; C.艰难梭菌0.25 μ g/ml; inconcuum，0.25 μ g/ml;产气荚膜梭菌0.125 μ g/ml;分枝，1 μ g/ml;真杆菌属，1 μ g/ml;乳杆菌属，> 32 μ g/ml，丙酸杆菌属，0.5微克/毫升;和消化链球菌属，0.25 mug/ml。达巴霉素对大多数菌株的活性比万古霉素高1至3倍。达巴霉素对测试的革兰氏阳性菌株表现出优异的活性，并保证临床评价。
Dalbavancin is a novel semisynthetic glycopeptide with enhanced activity against gram-positive species. Its comparative in vitro activities and those of nine comparator agents, including daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin, against 290 recent gram-positive clinical isolates strains, as determined by the NCCLS agar dilution method, were studied. The MICs of dallbavancin at which 90% of various isolates tested were inhibited were as follows: Actinomyces spp., 0.5 mug/ml; Clostridium clostridioforme, 8 mug/ml; C. difficile, 0.25 mug/ml; C. innocuum, 0.25 mug/ml; C. perfringens, 0.125 mug/ml; C. ramosum, 1 mug/ml; Eubacterium spp., 1 mug/ml; Lactobacillus spp., > 32 mug/ml, Propionibacterium spp., 0.5 mug/ml; and Peptostreptococcus spp., 0.25 mug/ml. Dalbavancin was 1 to 3 dilutions more active than vancomycin against most strains. Dalbavancin exhibited excellent activity against gram-positive strains tested and warrants clinical evaluation.